ctDNA monitoring found recurrence signals long before imaging turned positive
A blood-based liquid biopsy may give clinicians an earlier warning that lung cancer recurrence is underway, with molecular evidence appearing months before tumors became visible on scans. The study focused on circulating tumor DNA, or ctDNA, a fragment of tumor-derived genetic material that can be measured in blood samples after treatment.
In early-stage non-small cell lung cancer, surgery can be curative, yet recurrence remains a major problem. Standard follow-up relies heavily on imaging, especially CT scans, but imaging can only detect disease once enough tumor is present to be seen. A molecular test that identifies residual disease earlier could fill the gap between successful surgery and radiographic relapse.
This study points to a different window of surveillance. The blood test did not replace imaging, but it tracked the biology of recurrence before anatomy caught up.
How the blood assay works in treated lung cancer
Cancer cells shed DNA into the bloodstream, and those fragments can carry tumor-specific genetic changes. By looking for those signatures in blood samples collected over time, investigators can detect whether cancer DNA remains after treatment or reappears during surveillance.
That approach has a practical appeal in post-operative care. Instead of waiting for a lesion to become large enough for a scan, clinicians may be able to identify minimal residual disease through a blood draw. In this study, repeated sampling allowed the team to follow changes over time rather than depend only on scheduled imaging visits.
A positive ctDNA result meant tumor-associated DNA was detectable in blood, a finding that can indicate residual disease or recurrence. A negative result meant no ctDNA was found, although that does not prove cancer is absent. Some tumors shed very little DNA, and a small burden of disease may stay below the assay’s detection threshold.
Sensitivity, specificity, and the lead time over scans
The study included a retrospective cohort of 42 patients with stage IA lung adenocarcinoma. Among those who ultimately recurred, the assay detected ctDNA in 9 of 12 patients, producing a sensitivity of 75%. Specificity was 83%, and the negative predictive value reached 89%.
Those numbers matter because they show the test was not simply finding random molecular noise. It identified many of the patients who went on to recur, and negative results were linked to continued remission in most cases. The signal was strongest when ctDNA was paired with eventual clinical or radiologic relapse.
The most striking finding was timing. In patients with both a positive ctDNA result and confirmed recurrence, ctDNA appeared a median of 16.7 months before recurrence became clinically or radiologically apparent. That gap is long enough to matter in routine follow-up, especially for patients and clinicians trying to understand whether treatment really cleared the disease.
Why earlier molecular relapse detection could matter at the bedside
Earlier detection can change the conversation after surgery. A positive ctDNA result may identify patients at higher risk of relapse and prompt closer observation, consideration of additional therapy, or referral into a clinical trial. It could also help clinicians separate patients who may need intensified follow-up from those who are doing well and may not need further escalation.
There is another possible use case: avoiding overtreatment. A persistently negative ctDNA result may reassure clinicians that the risk of recurrence is low, especially when paired with reassuring imaging and pathology. In theory, that information could help spare some patients extra treatment and its side effects. In practice, a negative result would not be enough on its own to withhold therapy that is already recommended.
The same test could also clarify a difficult diagnostic problem. Whole-genome analysis may help distinguish a true recurrence from a new, independent lung primary, a distinction that can be hard to make using imaging and pathology alone.
Why the biology may be moving before the scan changes
The logic behind ctDNA surveillance fits lung adenocarcinoma biology. Tumor evolution begins long before a mass becomes visible on imaging, and early molecular events may persist as the disease progresses from precursor lesions to invasive cancer. If those molecular changes can be captured in blood, they may serve as a warning system for recurrence that is still too small to see.
Harvey Pass, MD, linked that idea to a broader model of temporal biomarkers, suggesting that circulating protein changes may one day work alongside cfDNA testing to improve prediction. The direction is important: rather than relying on a single test at a single time point, clinicians may eventually follow a sequence of molecular changes that mark progression earlier and with more precision.
What the current study can and cannot prove
This remains a retrospective study with a small sample size, so the results need confirmation in larger prospective cohorts before the test can be used routinely. The findings show association, not proof that acting on ctDNA will improve survival.
A positive result does not guarantee clinically meaningful recurrence, and a negative result does not rule out residual disease. Those are the two most important limitations for real-world use. The assay may miss tumors that shed little DNA, and it may also identify molecular disease that does not translate into an immediately actionable event.
Whether earlier intervention based on ctDNA actually improves outcomes is still unknown. That question will need randomized studies or carefully designed prospective trials that compare ctDNA-guided management with standard imaging-based follow-up.
What the next studies need to answer
Future work will need to define how often patients should be tested, which stage groups benefit most, and what clinicians should do when ctDNA turns positive before imaging does. It will also need to show whether the test reduces unnecessary treatment, identifies patients who truly need closer follow-up, or improves survival in any measurable way.
For now, the test looks best viewed as an adjunct to scans, not a substitute for them. It adds molecular detail to surveillance after surgery, and in this study it did so well before recurrence was visible on imaging.
The practical question is no longer whether ctDNA can detect recurrence earlier. The harder question is whether that earlier warning changes what happens next.